Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura (Q33369574)

26 July 2017

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura (English)

1 reference

Immune thrombocytopenic purpura

26 July 2017

1 reference

1 reference

1 reference

1 reference

4

James B Bussel

1 reference

26 July 2017

18

Ellis J Neufeld

1 reference

26 July 2017

9

Mignon L Loh

1 reference

26 July 2017

10

Bertil E Glader

1 reference

26 July 2017

Carolyn M Bennett

1

1 reference

26 July 2017

Zora R Rogers

2

1 reference

26 July 2017

Daniel D Kinnamon

3

1 reference

26 July 2017

Donald H Mahoney

5

1 reference

26 July 2017

Thomas C Abshire

6

1 reference

26 July 2017

Hadi Sawaf

7

1 reference

26 July 2017

Theodore B Moore

8

1 reference

26 July 2017

Maggie C McCarthy

11

1 reference

26 July 2017

Brigitta U Mueller

12

1 reference

26 July 2017

Thomas A Olson

13

1 reference

26 July 2017

Adonis N Lorenzana

14

1 reference

26 July 2017

William C Mentzer

15

1 reference

26 July 2017

George R Buchanan

16

1 reference

26 July 2017

Henry A Feldman

17

1 reference

26 July 2017

language of work or name

English

0 references

publication date

13 December 2005

1 reference

26 July 2017

1 reference

26 July 2017

107

1 reference

26 July 2017

7

1 reference

26 July 2017

2639-2642

1 reference

Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Grading of hemorrhage in children with idiopathic thrombocytopenic purpura

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

The spectrum of Evans' syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895391

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16352811

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16352811

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2005-08-3518

1 reference

26 July 2017

1 reference

26 July 2017

1 reference